Skip to main content
Premium Trial:

Request an Annual Quote

Over-Allotment Option Exercised in Affymetrix Senior Notes Offering; Stock Upgraded

NEW YORK (GenomeWeb News) – Affymetrix yesterday said that it had raised an additional $41.25 million from the exercise of an over-allotment option connected to last month’s senior convertible notes offering.
 
Last month, the firm raised $275 million from the sale of 3.5 percent senior convertible notes due 2038. The notes will be convertible into Affymetrix common stock at a rate of 33.191 shares per $1,000 principal amount of notes, which it said is equivalent to around $30.12 a share.
 
Affy said that it plans to use the funds for working capital and for general corporate purposes, which may include funding operations, acquisitions, and capital expenditures.
 
In separate news today, the firm’s stock was upgraded to “buy” from “neutral” by investment bank UBS.
The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.